Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGND) Share-based Compensation: 2009-2024

Historic Share-based Compensation for Ligand Pharmaceuticals (LGND) over the last 16 years, with Dec 2024 value amounting to $41.1 million.

  • Ligand Pharmaceuticals' Share-based Compensation fell 2.80% to $14.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $40.1 million, marking a year-over-year increase of 2.08%. This contributed to the annual value of $41.1 million for FY2024, which is 59.61% up from last year.
  • Per Ligand Pharmaceuticals' latest filing, its Share-based Compensation stood at $41.1 million for FY2024, which was up 59.61% from $25.7 million recorded in FY2023.
  • In the past 5 years, Ligand Pharmaceuticals' Share-based Compensation ranged from a high of $60.3 million in FY2022 and a low of $25.7 million during FY2023.
  • For the 3-year period, Ligand Pharmaceuticals' Share-based Compensation averaged around $42.4 million, with its median value being $41.1 million (2024).
  • Per our database at Business Quant, Ligand Pharmaceuticals' Share-based Compensation plummeted by 57.30% in 2023 and then soared by 59.61% in 2024.
  • Ligand Pharmaceuticals' Share-based Compensation (Yearly) stood at $30.7 million in 2020, then increased by 26.22% to $38.8 million in 2021, then skyrocketed by 55.44% to $60.3 million in 2022, then crashed by 57.30% to $25.7 million in 2023, then surged by 59.61% to $41.1 million in 2024.